Monte Rosa Therapeutics (GLUE) Research & Development (2020 - 2026)

Monte Rosa Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $9.6 million for Q1 2026.

• On a quarterly basis, Research & Development rose 137.35% year-over-year to $9.6 million in Q1 2026; TTM through Mar 2026 was $93.9 million, a 140.68% increase from a year earlier, with the FY2025 full-year figure at $141.5 million, up 880.46% from the prior year.
• Research & Development declined to $9.6 million in Q1 2026 per GLUE's latest filing, from $42.0 million in the prior quarter.
• Across five years, Research & Development topped out at $42.0 million in Q4 2025 and bottomed at -$37.7 million in Q4 2023.
• The 5-year median for Research & Development is $21.3 million (2022), against an average of $17.1 million.
• Across the five-year window, Research & Development tumbled 251.73% in 2023 and soared 982.21% in 2025, its largest moves.
• Year by year, Research & Development stood at $24.9 million in 2022, then tumbled by 251.73% to -$37.7 million in 2023, then surged by 110.28% to $3.9 million in 2024, then surged by 982.21% to $42.0 million in 2025, then sank by 77.16% to $9.6 million in 2026.
• Per Business Quant, the three latest GLUE Research & Development figures stand at $9.6 million (Q1 2026), $42.0 million (Q4 2025), and $36.7 million (Q3 2025).